

FAST Mouse Cognition Enhancement and Neuroprotection Assay for Alzheimer's Disease

SynAging uses proprietary amyloid- β oligomer (A β O) preparations to induce Alzheimer's disease in mice following icv injection of 50 pmol. A β O cognition impairment of the following amyloid peptides has been validated *in vivo*:


A β_{1-42} , A β_{1-40} , A β_{11-40} , A β_{11-42} , pE(3)A β_{3-42} , pE(3)A β_{3-40} , A β_{4-40} , A β_{4-42}

Others can be evaluated upon request.

SynAging's A β O preparations induce full cognitive deficiency within four days which remains stable over multiple months. SynAging has verified the cognitive deficiency of A β O injected mice in the following assay formats:


- Y-Maze (pre-frontal cortex)
- Novel Object Recognition (perirhinal cortex9)
- Morris Water Maze (hippocampus)
- Spatial Recognition Test (hippocampus)

For a FAST evaluation of test compounds *in vivo*, we recommend the double-Y-maze model. In this, mice are icv injected with vehicle or A β O (day 0) and test compound treated from e.g. day -1 to day 7. The first Y-maze is performed on day 4, documenting symptomatic improvements during treatment.



Four days after icv injection of A β O, alternation behavior in mice is significantly decreased compared to vehicle injection. Compound T1 and T2 (both given po), as well as the positive control humanin (icv) prevent this deficiency.


Drug treatment is stopped on day seven and a second Y-maze assay is run on day ten investigating disease modifying properties.



The deficiency in alternation behavior on day 10 in A β O mice without compound treatment is unchanged. Treatment with T1 had no lasting effect, whereas T2, as well as humanin treatment show clear disease modification.

Timing: results are available one month after study start incorporated in the draft report sent to clients. Final reports on test items, including client feedback are provided two weeks later.

SynAging's model shows very high reproducibility of A β O induced cognitive decline. Quality control has been performed over three year in 20 independent experiments using 11 batches of A β_{1-42} oligomers. Mice were submitted to the Y-maze assay on day 4. While vehicle injected mice showed 66.1 \pm 0.6 % alternation behavior, A β O injected mice showed consistently reduced alternation at 53.0 \pm 0.4 % (mean \pm SEM).



SynAging SAS: Your partner in naturally induced phenotypic models, accelerating drug discovery for proteopathic CNS diseases